PL4026532T3 - Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną - Google Patents

Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną

Info

Publication number
PL4026532T3
PL4026532T3 PL21211390.6T PL21211390T PL4026532T3 PL 4026532 T3 PL4026532 T3 PL 4026532T3 PL 21211390 T PL21211390 T PL 21211390T PL 4026532 T3 PL4026532 T3 PL 4026532T3
Authority
PL
Poland
Prior art keywords
neurotoxin
tryptophan
tyrosine
stabilized
liquid formulation
Prior art date
Application number
PL21211390.6T
Other languages
English (en)
Inventor
Anders Jarstad
Anna FRIIS
Ulf Stahl
Ann GURELL
Barbro AGREN
Emilia EDSTROM
Andrew Pickett
Original Assignee
Ipsen Biopharm Limited
Galderma Holding SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Limited, Galderma Holding SA filed Critical Ipsen Biopharm Limited
Publication of PL4026532T3 publication Critical patent/PL4026532T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21211390.6T 2016-05-27 2017-05-26 Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną PL4026532T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016062085 2016-05-27

Publications (1)

Publication Number Publication Date
PL4026532T3 true PL4026532T3 (pl) 2026-03-16

Family

ID=56289455

Family Applications (3)

Application Number Title Priority Date Filing Date
PL21211390.6T PL4026532T3 (pl) 2016-05-27 2017-05-26 Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną
PL20152386T PL3679946T3 (pl) 2016-05-27 2017-05-26 Ciekłe formulacje neurotoksyny stabilizowane tryptofanem lub tyrozyną
PL17728095T PL3463432T3 (pl) 2016-05-27 2017-05-26 Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL20152386T PL3679946T3 (pl) 2016-05-27 2017-05-26 Ciekłe formulacje neurotoksyny stabilizowane tryptofanem lub tyrozyną
PL17728095T PL3463432T3 (pl) 2016-05-27 2017-05-26 Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną

Country Status (31)

Country Link
US (5) US20190183988A1 (pl)
EP (3) EP3679946B1 (pl)
JP (1) JP7053498B2 (pl)
KR (2) KR102423739B1 (pl)
CN (2) CN111701010B (pl)
AR (1) AR108631A1 (pl)
AU (1) AU2017270359B2 (pl)
CA (1) CA3025437A1 (pl)
CY (2) CY1124237T1 (pl)
DK (3) DK3679946T3 (pl)
EA (1) EA038124B1 (pl)
ES (3) ES2911124T3 (pl)
FI (1) FI4026532T3 (pl)
GE (2) GEP20207139B (pl)
HR (3) HRP20251606T1 (pl)
HU (2) HUE052023T2 (pl)
IL (2) IL285190B (pl)
LT (3) LT4026532T (pl)
MX (1) MX392529B (pl)
PL (3) PL4026532T3 (pl)
PT (3) PT3463432T (pl)
RS (3) RS61340B1 (pl)
RU (1) RU2741497C9 (pl)
SA (1) SA518400513B1 (pl)
SG (1) SG11201810561YA (pl)
SI (3) SI3679946T1 (pl)
SM (3) SMT202100003T1 (pl)
TW (1) TWI777955B (pl)
UA (1) UA123679C2 (pl)
WO (1) WO2017203038A1 (pl)
ZA (1) ZA201807904B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
CN102869373B (zh) 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
WO2019126502A1 (en) * 2017-12-20 2019-06-27 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
UY38744A (es) 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
US20230165946A1 (en) * 2020-04-08 2023-06-01 Medytox Inc. Botulinum toxin pre-filled injectable formulation that facilitates discharge rate control and is stable
CN116440281A (zh) * 2022-01-07 2023-07-18 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物
JP2025500698A (ja) * 2022-01-14 2025-01-09 ガルデルマ・ホールディング・エスアー 中等度から最重度の眉間皺及び外眼角皺の治療
CN119031902A (zh) 2022-02-15 2024-11-26 莫茨药物股份两合公司 液体肉毒杆菌毒素制剂及其用途
IL326140A (en) 2023-08-10 2026-03-01 Merz Pharma Gmbh & Co Kgaa Liquid formulation of botulinum toxin and its use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
ES2237551T3 (es) 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7163671B2 (en) * 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP1786459B1 (en) * 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
ES2526913T3 (es) * 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
CA2690773C (en) * 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
US9274121B2 (en) 2011-06-01 2016-03-01 Biomadison, Inc. Non-FRET botulinum assay
LT2761065T (lt) 2011-09-29 2018-01-10 Cellsnap, Llc Kompozicijos ir būdai toksigeniškumo testavimui
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
WO2015044416A1 (en) 2013-09-30 2015-04-02 Galderma S.A. Prostate cancer treatment
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Also Published As

Publication number Publication date
EP3463432A1 (en) 2019-04-10
CA3025437A1 (en) 2017-11-30
US20240050539A1 (en) 2024-02-15
RS62832B1 (sr) 2022-02-28
HRP20251606T1 (hr) 2026-02-13
MX2018014631A (es) 2019-06-12
HRP20202070T1 (hr) 2021-02-19
HUE052023T2 (hu) 2021-04-28
LT3463432T (lt) 2021-01-25
PT3679946T (pt) 2022-01-14
EA201892493A1 (ru) 2019-04-30
CN111701010B (zh) 2023-09-26
SI3679946T1 (sl) 2022-04-29
US12285468B2 (en) 2025-04-29
EP3463432B1 (en) 2020-10-07
SA518400513B1 (ar) 2022-11-03
CN111701010A (zh) 2020-09-25
US20250255943A1 (en) 2025-08-14
US20230181702A1 (en) 2023-06-15
SMT202100003T1 (it) 2021-03-15
KR102399451B1 (ko) 2022-05-23
PL3679946T3 (pl) 2022-05-30
RS61340B1 (sr) 2021-02-26
FI4026532T3 (fi) 2026-02-03
CY1124916T1 (el) 2023-01-05
SI3463432T1 (sl) 2021-02-26
TWI777955B (zh) 2022-09-21
DK4026532T3 (da) 2025-12-08
RU2018142149A3 (pl) 2020-07-23
US20210330765A1 (en) 2021-10-28
JP7053498B2 (ja) 2022-04-12
US20190183988A1 (en) 2019-06-20
GEP20207139B (en) 2020-07-27
RU2741497C2 (ru) 2021-01-26
SG11201810561YA (en) 2018-12-28
ES2911124T3 (es) 2022-05-17
IL263173A (en) 2018-12-31
DK3463432T3 (da) 2021-01-04
IL263173B (en) 2021-08-31
PT3463432T (pt) 2021-01-12
IL285190B (en) 2022-07-01
CN109562148A (zh) 2019-04-02
ES2846350T3 (es) 2021-07-28
EP4026532B1 (en) 2025-11-26
SI4026532T1 (sl) 2026-01-30
BR112018074311A2 (pt) 2019-10-01
EP3679946A1 (en) 2020-07-15
KR102423739B1 (ko) 2022-07-21
PL3463432T3 (pl) 2021-04-19
HRP20220024T1 (hr) 2022-04-01
MX392529B (es) 2025-03-21
LT4026532T (lt) 2026-01-12
JP2019517481A (ja) 2019-06-24
GEAP202014939A (en) 2020-04-10
ES3062544T3 (en) 2026-04-13
RS67508B1 (sr) 2025-12-31
KR20190022548A (ko) 2019-03-06
RU2018142149A (ru) 2020-06-29
ZA201807904B (en) 2020-05-27
KR20220054887A (ko) 2022-05-03
CY1124237T1 (el) 2022-07-22
DK3679946T3 (da) 2022-02-07
EP3679946B1 (en) 2022-01-05
TW201742632A (zh) 2017-12-16
WO2017203038A1 (en) 2017-11-30
NZ748626A (en) 2025-05-02
EA038124B1 (ru) 2021-07-09
SMT202500479T1 (it) 2026-01-12
AU2017270359A1 (en) 2018-12-13
AR108631A1 (es) 2018-09-12
RU2741497C9 (ru) 2021-04-30
NZ788585A (en) 2025-12-19
SMT202200080T1 (it) 2022-03-21
HUE057640T2 (hu) 2022-05-28
EP4026532A1 (en) 2022-07-13
IL285190A (en) 2021-08-31
PT4026532T (pt) 2026-02-03
US20230190892A9 (en) 2023-06-22
LT3679946T (lt) 2022-02-10
AU2017270359B2 (en) 2023-09-21
UA123679C2 (uk) 2021-05-12

Similar Documents

Publication Publication Date Title
IL285190A (en) A liquid neurotoxin preparation stabilized by tryptophan or tyrosine
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
EP3310776A4 (en) BRUTON TYROSINE KINASE HEMMER
PT3334747T (pt) Formulação de gonadotrofina líquida estável
EP3390626A4 (en) LIQUID FORMULATION OF ALPHA AMYLASE
EP3556343A4 (en) OIL-IN-WATER COMPOSITION
EP3405192A4 (en) BRUTON TYROSINE KINASE HEMMER
EP3558000C0 (en) COMPOSITIONS CONTAINING ACETIC ACID AND HYPOCHLOROUS ACID
EP3449846A4 (en) DRILL OF A PIEZO SURGERY
EP3395325A4 (en) LIQUID COSMETIC COMPOSITION
DK3356790T3 (da) System og fremgangsmåde til den optiske måling af stabiliteten og aggregeringen af partikler
MA52595A (fr) Formulation liquide stable de gonadotrophines
EP3261777A4 (en) FLÜSSIGKEITSRAFFINIERUNG
EP3385326A4 (en) AQUEOUS POLYTETRAFLUORETHYLENE DISPERSION
EP3398262A4 (en) MICRO-OUTER CHARACTERIZATION AND SELECTION
EP3685821A4 (en) LIQUID HAIR COLOR COMPOSITION
DK3474821T3 (da) Flydende farmaceutisk sammensætning af clonidin
FR3039396B1 (fr) Base de formulation cosmetique concentree
EP3511327A4 (en) TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF
DK3330267T3 (da) Salt af quinazolinderivat eller crystal deraf samt fremgangsmåde til fremstilling af salt af quinazolinderivat eller crystal deraf
EP3439650A4 (en) LIQUID PHOSPHAPLATIN FORMULATIONS
EP3305296A4 (en) AQUEOUS LIQUID FORMULATION
EP3574111A4 (en) Assay performance systems including aqueous sample stabilization
EP3562512A4 (en) FORMULATION FOR THE STABILIZATION OF THERAPEUTIC BIOLOGICAL AGENTS
EP3593807A4 (en) LIQUID FORMULATION BASED ON ALGINATE